BPG is committed to discovery and dissemination of knowledge
Featured Articles
6/16/2022 1:22:12 PM | Browse: 37 | Download: 51
Publication Name World Journal of Gastroenterology
Manuscript ID 74589
Country/Territory United States
2021-12-29 03:11
Peer-Review Started
2021-12-29 03:12
To Make the First Decision
Return for Revision
2022-03-10 05:38
2022-03-25 03:06
Second Decision
2022-04-29 03:12
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2022-04-30 07:34
Articles in Press
2022-04-30 07:34
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript
2022-05-25 08:38
Publish the Manuscript Online
2022-06-16 13:07
ISSN 1007-9327 (print) and 2219-2840 (online)
Open Access This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright © The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Oncology
Manuscript Type Minireviews
Article Title Up to seven criteria in selection of systemic therapy for hepatocellular carcinoma
Manuscript Source Invited Manuscript
All Author List Tarik Silk, Mikhail Silk and Jennifer Wu
Funding Agency and Grant Number
Corresponding Author Jennifer Wu, MD, Associate Professor, Attending Doctor, Division of Hematology and Oncology, Perlmutter Cancer Center of NYU Langone Health, NYU School of Medicine, 462 First Ave, BCD556, New York, NY 10016, United States. jennifer.wu@nyulangone.org
Key Words Chemoembolization; Hepatocellular carcinoma; Immunotherapy; Drug combinations; Review; Medical oncology
Core Tip Barcelona clinic liver cancer intermediate stage disease that exceeds “the up to seven” criteria, especially with lesions larger than 5 cm, is less likely to respond to transarterial chemoembolization (TACE) alone and is therefore a disease that may respond better to systemic therapy. The use of “the up to seven” criteria can be a helpful guidepost for when to consider systemic therapy alone or in addition to TACE. With the recent breakthroughs in immunotherapy for advanced hepatocellular carcinoma which clearly demonstrated overall survival advantage over single agent tyrosine kinase inhibitors sorafenib, it is promising that the use of immunotherapy would likely lead to better outcome when used in intermediate disease.
Publish Date 2022-06-16 13:07
Citation Silk T, Silk M, Wu J. Up to seven criteria in selection of systemic therapy for hepatocellular carcinoma. World J Gastroenterol 2022; 28(23):2561-2568
URL https://www.wjgnet.com/1007-9327/full/v28/i23/2561.htm
DOI https://dx.doi.org/10.3748/wjg.v28.i23.2561
Full Article (PDF) WJG-28-2561.pdf
Full Article (Word) WJG-28-2561.docx
Manuscript File 74589_Auto_Edited.docx
Answering Reviewers 74589-Answering reviewers.pdf
Audio Core Tip 74589-Audio core tip.m4a
Conflict-of-Interest Disclosure Form 74589-Conflict-of-interest statement.pdf
Copyright License Agreement 74589-Copyright license agreement.pdf
Peer-review Report 74589-Peer-review(s).pdf
Scientific Misconduct Check 74589-Bing-Fan JR-2.png
Scientific Editor Work List 74589-Scientific editor work list.pdf